NCT04731051 - The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients | Biotech Hunter

Timeline

Start Date

October 31, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

December 31, 2022

Conditions

2019 Novel Coronavirus

Interventions

DRUG

HCQ01

HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization

DRUG

standard of care (SOC) for COVID-19

Standard of care (SOC) for COVID-19

Trial Locations (1)

King Hussein Cancer Center, Amman